PPARA and Abnormal retinal morphology: Recently, it has been reported that the PPARα/γ dual agonist saroglitazar, developed by Zydus cadila and approved in India, is patented for treating retinal diseases caused by inflammation, macular degeneration, and neovascularization [109].